Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 185.60% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 185.60% | -- | |||
| Cost of Revenue | -82.82% | 14.53% | |||
| Gross Profit | 84.10% | -13.99% | |||
| SG&A Expenses | 40.30% | 26.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.44% | 17.97% | |||
| Operating Income | -15.89% | -17.58% | |||
| Income Before Tax | -19.49% | -20.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.49% | -20.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.49% | -20.07% | |||
| EBIT | -15.89% | -17.58% | |||
| EBITDA | -16.00% | -17.59% | |||
| EPS Basic | -18.62% | -17.99% | |||
| Normalized Basic EPS | -18.61% | -18.02% | |||
| EPS Diluted | -18.62% | -17.99% | |||
| Normalized Diluted EPS | -18.61% | -18.02% | |||
| Average Basic Shares Outstanding | 0.74% | 1.76% | |||
| Average Diluted Shares Outstanding | 0.74% | 1.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||